We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Kleo Pharmaceuticals announced CD38-ARM, a CD38 targeting antibody recruiting molecule (ARM™) to treat multiple myeloma, will be its first product candidate to move into the clinic with anticipated human studies to commence in 2020.